文献速递技术与安全PET

诊疗一体化的近期进展与未来挑战

Recent advances in theranostics and challenges for the future.
PubMed 文献 · Br J Radiol · 2018-03-29

本文综述过去一年诊疗一体化核肿瘤学的进展。NETTER-1 3期随机对照试验首次为68镓/177镥-DOTA-奥曲肽肽受体放射性核素治疗中肠神经内分泌肿瘤提供1b级疗效与安全性证据;68镓/177镥-前列腺特异性膜抗原诊疗一体化在多中心2期研究中用于终末期转移性去势抵抗性前列腺癌结果令人鼓舞,但现有回顾性非对照数据不足以供监管机构正式评估。

要点

  • NETTER-1 3期随机对照试验首次确立68镓/177镥-DOTA-奥曲肽肽受体放射性核素治疗中肠神经内分泌肿瘤的1b级疗效与安全性证据。
  • 68镓/177镥-前列腺特异性膜抗原诊疗一体化在多中心2期研究中用于终末期转移性去势抵抗性前列腺癌结果令人鼓舞。
  • 现有回顾性非对照数据不足以供监管机构正式评估,需与肿瘤科、泌尿科及制药企业合作设计对照临床试验。

核心结论

  • 诊疗一体化核肿瘤学在NETTER-1 3期随机对照试验发表后正迈向神经内分泌肿瘤常规临床管理。
  • 68镓/177镥-前列腺特异性膜抗原诊疗一体化在多中心2期研究中用于终末期转移性去势抵抗性前列腺癌结果令人鼓舞,但现有回顾性非对照数据不足以供监管机构正式评估。
  • 最终目标是延长癌症患者生存并改善生活质量,需肿瘤科、核医学、放射科、剂量物理师、制药企业及患者密切合作。

研究设计与样本

  • 综述,总结过去一年诊疗一体化进展并讨论促进及时建立证据基础的策略。
  • 引用NETTER-1 3期随机对照试验,首次确立68镓/177镥-DOTA-奥曲肽肽受体放射性核素治疗中肠神经内分泌肿瘤的1b级疗效与安全性证据。
  • 引用68镓/177镥-前列腺特异性膜抗原诊疗一体化管理终末期转移性去势抵抗性前列腺癌的多中心2期研究。

诊断标准与关键数值

  • NETTER-1 3期随机对照试验为68镓/177镥-DOTA-奥曲肽肽受体放射性核素治疗中肠神经内分泌肿瘤提供1b级疗效与安全性证据。
  • 68镓/177镥-前列腺特异性膜抗原诊疗一体化在多中心2期研究中用于终末期转移性去势抵抗性前列腺癌结果令人鼓舞。
  • 现有回顾性非对照数据不足以供监管机构正式评估。

临床应用与阅片要点

  • 作者认为需与肿瘤科和泌尿科合作、并与制药企业协作,设计并实施监管批准及最终报销所需的对照临床试验。
  • 作者认为希望在恶性疾病更早期提供诊疗一体化治疗,此时获益可能更大。

局限性

  • 现有回顾性非对照数据不足以供监管机构正式评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Theranostic nuclear oncology is on the cusp of adoption into routine clinical management of neuroendocrine tumours (NETs) following publication of the Phase 3 randomised controlled trial, NETTER-1. For the first time, level 1b evidence of efficacy and safety of 68-gallium/177-lutetium-DOTA-octreotate peptide receptor radionuclide therapy, of mid-gut neuroendocrine tumours was established. Multicentre Phase 2 studies of 68-gallium/177-lutetium-prostate specific membrane antigen theranostic approaches to management of end-stage metastatic castrate-resistant prostate cancer, are also very encouraging. However, the retrospective uncontrolled data currently available are inadmissible for formal regulatory agency evaluation. The challenge is to engage with oncologists and urologists, and to collaborate with the pharmaceutical industry, to design and perform the controlled clinical trials required for regulatory approval, and eventual reimbursement for theranostic nuclear oncology procedures. Strategies to facilitate timely establishment of an evidence base are considered in this review of theranostic advances over the past year. The prime objective is the provision of novel, effective, safe, personalised, tumour-targeted molecular theranostic management of metastatic castrate-resistant prostate cancer, and other cancers, such as non-Hodgkin lymphoma, which express the appropriate molecular receptor tumour targets. It would also be desirable to offer theranostic treatments at an earlier stage of malignant disease when the benefit is likely to be greater. The ultimate goal of theranostic nuclear oncology is to prolong survival and to improve quality of life for cancer patients worldwide. This may only be achieved through close collaboration between oncologists, nuclear physicians, radiologists, dosimetric physicists, Pharma, and, above all, with the patients themselves, in ways which are explored in this review.

来源:Br J Radiol,查看原文。版权归原作者所有。

引用

  1. Turner JH. Recent advances in theranostics and challenges for the future. Br J Radiol. 2018. PMID: 29565650. doi:10.1259/bjr.20170893

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。